Penn spinout Linnaeus Therapeutics has raised another $1.6 million in financing, bringing its cumulative funding total to over $13 million since 2018.
The company, co-founded in 2016 by Todd Ridky, MD, PhD, Associate Professor of Dermatology at Penn Medicine, and Christopher Natale, PhD, PhD, a prior graduate student in the Ridky Lab, focuses on developing small molecule oncology therapeutics.
Linnaeus has received orphan drug designation from the FDA for its lead drug candidate, LNS8801, and has a clinical partnership with Merck to evaluate the drug in combination with Keytruda for patients suffering from advanced cancer. Read more here.